Decoding 5 Analyst Evaluations For Liquidia
Portfolio Pulse from Benzinga Insights
Liquidia (NASDAQ:LQDA) has received mixed analyst ratings over the past three months, with a total of 4 bullish and 1 somewhat bearish rating. The 12-month price target average has increased by 22.64% to $18.8, with a high of $30.00 and a low of $3.00. Analysts from Needham, Ladenburg Thalmann, B of A Securities, and Wedbush have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Liquidia is a biopharmaceutical company focusing on pulmonary hypertension treatments and has shown a revenue growth rate of 16.21% as of September 30, 2023, but trails behind industry peers and has a net margin of -429.31% and ROE of -29.06%.

January 05, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Liquidia has received mixed analyst ratings, with a recent increase in the average price target to $18.8. The company has shown revenue growth but faces profitability challenges with a high net margin loss and low ROE.
The mixed analyst ratings and the increase in the average price target suggest a neutral short-term impact on LQDA's stock price. While the bullish ratings and raised targets could indicate a positive sentiment, the somewhat bearish rating and the company's below-average profitability metrics may temper investor enthusiasm. The high relevance is due to the direct mention of LQDA and the detailed analysis of its financials and analyst ratings. The importance is high as analyst ratings can influence investor decisions, but not at the maximum due to the presence of one somewhat bearish rating. The confidence level is high as the analysis is based on recent and specific analyst actions and financial data.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100